Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors
Open Access
- 16 February 2021
- journal article
- Published by Bentham Science Publishers Ltd. in Clinical Practice and Epidemiology in Mental Health
- Vol. 17 (1), 1-7
- https://doi.org/10.2174/1745017902117010001
Abstract
Background: Extrapyramidal Symptoms (EPS) are unwanted symptoms commonly originating from the use of certain medications. The symptoms can range from minimal discomfort to permanent involuntary muscular movements. The aims of the study were to examine the incidence of drug-induced extrapyramidal symptoms (di-EPS), associated risk factors, and clinical characteristics. Methods: This is a retrospective, observational study of di-EPS conducted in outpatient clinics of Jordan using the longitudinal health database (Hakeem®) for data collection. Patients who received drugs with the risk of EPS during the period 2010-2020 were included and followed. Patients with any of the known underlying conditions that may cause EPS or were currently taking drugs that may mask the symptoms were excluded. Gender and age-matched control subjects were included in the study. The Statistical Package for Social Science (SPSS®) version 26 was used for data analysis. Results: The final dataset included 34898 exposed patients and 69796 matched controls. The incidence of di-EPS ranged from 9.8% [Amitriptyline 25mg] to 28.9% (Imipramine 25mg). Baseline factors associated with a significantly higher risk of developing di-EPS were age {HR: 1.1 [95%CI: 0.8-1.2, p=0.003], smoking {HR: 1.7 (95%CI: 1.3-2.2), p=0.02}, tremor history {HR: 7.4 (95%CI: 5.9-8.3), p=.002} and history of taking antipsychotics {HR: 3.9, (95% CI: 2.5-4.6), p=0.001}. Patients taking paroxetine {HR: 8.6 [95%CI: 7.4-9.8], p=.0002},imipramine {HR: 8.3, [7.1-10.5], p=0.01}, or fluoxetine {HR: 8.2 (95%CI: 6.8-9.3), p=.006} had a significantly higher risk of developing di-EPS compared to patients taking citalopram. Myoclonus, blepharospasm, symptoms of the basal ganglia dysfunction, and organic writers' cramp were reported among participants. Conclusion: Patients treated with paroxetine, imipramine, fluoxetine, or clomipramine had a higher risk of developing di-EPS than patients treated with citalopram. The difference in gender was not significantly related to di-EPS development. Whereas age, smoking, and history of taking antipsychotics were significantly associated with di-EPS development. Key findings: • High incidence of drug-induced extrapyramidal symptoms (di-EPS) was reported • Age, smoking, tremor history, and history of taking antipsychotics were risk factors of drug-induced extrapyramidal symptoms. • Patients taking paroxetine, imipramine or fluoxetine had a significantly higher risk of developing di-EPS compared to patients taking citalopramKeywords
This publication has 37 references indexed in Scilit:
- Investigation of Cigarette Smoking among Male Schizophrenia PatientsPLOS ONE, 2013
- Treatment-emergent adverse events associated with atypical antipsychoticsExpert Opinion on Pharmacotherapy, 2011
- Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in SchizophreniaJournal of Clinical Psychopharmacology, 2010
- Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunctionMovement Disorders, 2006
- Risk Factors for Extrapyramidal Symptoms During Treatment With Selective Serotonin Reuptake Inhibitors, Including Cytochrome P-450 Enzyme, and Serotonin and Dopamine Transporter and Receptor PolymorphismsJournal of Clinical Psychopharmacology, 2006
- Side effects of antidepressants: an overview.Cleveland Clinic Journal of Medicine, 2006
- Extrapyramidal Symptoms with Atypical AntipsychoticsDrug Safety, 2005
- Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiologyActa Psychiatrica Scandinavica, 1992
- Smoking and movement disorders in psychiatric patientsBiological Psychiatry, 1991
- Metoclopramide-induced movement disorders. Clinical findings with a review of the literatureArchives of Internal Medicine, 1989